← BackVERACYTE, INC. · Medical LaboratoriesVCYT
Low riskNext report: In 6 days (est.)
The short versionA profitable company with growing sales.
Going well
- Sales up 16% in the latest quarter vs a year ago
- Profitable
- Sales up 16% last year
Money moves
- Insiders sold $81K in the last 30 days, all through pre-planned sales
- Institutions added 0.9% to their holdings in the quarter ending June 2026 (203 bought, 163 sold)
- Held by Ray Dalio (Bridgewater), Cathie Wood (ARK Invest)
Facts from SEC filings, not a recommendation.
What the price means
Price as of Oct 26
$48.24+0.7% that day
- Company value
- $3.9B
- Share price times all shares
- Price vs profit (P/E)
- 34.5x
- You pay about $34 for each $1 of yearly profit
- Price vs sales
- 6.9x
- Company value is 6.9 times a year of sales
- Cash vs value
- 8%
- Cash as a share of company value
From VCYT's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.
The business over time
Last 12 quarters, from SEC filings
Sales, Jun '26$150.3M+15% vs a year earlier
Sep '23Tap a barJun '26
Last 12 months: $561.9M, up 17% from the 12 months before. Over 5 years, sales grew about 35% a year.
Business quality
The checklist Warren Buffett-style investors use. Annual numbers for 2025.- MissReturn on equity 15%+Earns a lot on the money owners have in the business.5.3%
- PassDebt under half of equityNot relying on borrowed money.No debt reported
- PassNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.12.8%
- MissProfitable every yearSteady profits, not one good year.2 of 10 years
- PassFree cash flow positiveBrings in more cash than it spends to run and grow.$126.6M
- MissShare count not growingNot diluting owners. Falling means buybacks.+12.6% in 3 years
- PassGross margin 40%+Pricing power: sells for well above what it costs to make.70.1%
- Revenue
- $517.1M
- +16.0% vs prior year
- 5-year growth
- +34.5%/yr
- revenue, per year
- Total debt
- None
- 0.00x equity
- Current ratio
- 8.15x
- short-term assets / bills due
From annual reports filed with the SEC. A checklist is a starting point for research, not a verdict.
Latest quarter
Quarter ended Jun 30, 2026- Revenue
- $150.3M
- +15.5% YoY
- EPS
- $0.31
- vs -$0.01
- Op. margin
- 15.3%
- +19.3 pts
- Gross margin
- 72.2%
- +3.2 pts
- Free cash flow
- $43.0M
- Share count
- +4.7%
- vs a year ago
Insider rating
Last 90 days
48Mixed
- Pre-planned sales of $81K (weaker signal)
50 is neutral. Buying by more insiders, top executives and bigger stakes raises it. Selling lowers it; pre-planned sales count less.
Weekly insider trend13 weeks agoBoughtSoldThis week
Filing buzz
Last 7 days vs normal
0/ 100
- This week
- 2
- Normal week
- 1.6
- vs normal
- 1.3x
SEC filings of any kind. 50 means a normal week.
Institutional ownership
■Steady+0.9%Institutions added 0.9% to their holdings. 203 bought, 163 sold. 2 quarters of net buying in a row.
Shares held by institutions89.2M
Sep '24Jun '26
Share count growthYearly rate, last 3 years
+3.4%Cash runwayAt last year's cash burn
Cash flow positiveDebt to equityLatest balance sheet: debt compared with what owners have
No debt reportedShares outstandingLatest reported
80MNext reportIn 6 days (est.)Estimated from the same quarter last year
- Results filedJul 30
- Results filedMay 5
- Results filedFeb 25
- Results filedJan 12
- Results filedNov 4, 2025
Flags and big holders
Offerings 6 months, flags 12 months, holders 90 days
No offerings, red flags or new big holders. Clean record.
Insider trades
Open-market buys and sells, last 90 days Bought$00 insiders
Sold$81K1 insider, 1 pre-planned
| Insider | Trade | Shares | Avg price | Value | Owns after | Date |
|---|
Muna BhanjiDirector | Sell | 2K | $43.70 | $81K | 41K | |
- -4.4% of their holdings
- Pre-planned sale (10b5-1)
- Filed 1 day after
|
"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.
Latest filings
Straight from SEC EDGAR
SoldMuna BhanjiDirector
1,864 shares at $43.70 · $81K
- -4% of holdings
- Now owns 40,854 shares
- Pre-planned sale (10b5-1)
- Filed 1 day after trade
SoldJohn LeiteGlobal Chief Commercial Off
4,015 shares at $40.00 · $161K
- -3% of holdings
- Now owns 124,329 shares
- Pre-planned sale (10b5-1)
- Filed 1 day after trade
SoldJens HolsteinDirector
5,000 shares at $40.95 · $205K
- -15% of holdings
- Now owns 27,471 shares
- Pre-planned sale (10b5-1)
- Filed 2 days after trade
Shares withheld for taxesMarc StapleyChief Executive Officer, Director
8,782 shares at $44.88 · $394K
- -2% of holdings
- Now owns 432,073 shares
- Filed 2 days after trade
SoldAnnie McguireEVP, General Counsel
3,254 shares at $43.09 avg ($42.79 to $43.67) · $140K
- -2% of holdings
- Now owns 131,160 shares
- Pre-planned sale (10b5-1)
- 2 transactions
- Filed same day
- Also: Shares withheld for taxes
SoldRebecca ChambersChief Financial Officer
3,652 shares at $43.10 avg ($42.81 to $43.71) · $157K
- -2% of holdings
- Now owns 166,025 shares
- Pre-planned sale (10b5-1)
- 2 transactions
- Filed same day
- Also: Shares withheld for taxes